spacer
home > ict > winter 2021 > the precision paradigm
PUBLICATIONS
International Clinical Trials

The Precision Paradigm


3D bioprinting is proving to be a useful tool in healthcare research. From drug development and personalised medicine to bioengineered organs, the additive manufacturing process is enabling medical discoveries and new solutions to many of the grand challenges of our time. In areas such as cancer research and tissue regeneration, 3D bioprinting is providing the ability to research biological processes in more physiologically relevant cellular microenvironments and in specific geometrical biomimicry arrangements. This is allowing scientists to think differently when approaching biological questions, such as how to improve modelling of human diseases or how to reduce animal testing numbers. Current state-of-the-art 3D bioprinting systems are rapidly being improved upon within the community, and innovations that lie ahead may one day result in products that reach a clinic near you.

Drug Development and Personalised Medicine

The process of drug development, starting from preclinical target identification to regulatory approval for marketing, is a long journey which is often very competitive, costly, and challenging. The process demands rigorous laboratory screening of drug candidates utilising in vitro systems followed by animal testing before the promising drug candidates are tested in four phases of human clinical trials. Clinical trials are resource-intensive and can take many years at price tags as high as billions of dollars. Even if 10 viable drug candidates are identified for human trials, the majority will not make it to market. Given this high attrition rate, there is certainly an unmet need to develop improved model systems to evaluate drugs that better predict the clinical outcomes.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Erik Gatenholm is the CEO and Co-Founder of CELLINK. Erik was recently placed on MIT's Innovators Under 35 list for his achievements within life science and as an entrepreneur and has also been listed on Forbes 30 Under 30.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Nemera joins IPAC-RS as an Associate Member

Nemera is excited to announce that it has become an Associate Member of the International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS). Nemera’s decision to join IPAC-RS is part of its commitment to advance science and innovation. Nemera is committed to enhancing better patient outcomes by seeking innovative solutions and contributing actively to discussions about the future of drug delivery devices. Its membership in IPAC-RS will facilitate this important commitment.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement